PW Medtech

PW Medtech holds leading market positions in China for infusion sets, blood purification products such as hemodialyzers and hemoperfutors, and regenerative medical biomaterials. The company has a strong R&D pipeline focused on high-growth segments of the Chinese medical device industry. It was among the first to receive regulatory approval for several innovative infusion set technologies and high-flux hemodialyzers in China. Its regenerative materials are used across multiple surgical specialties including hernia repair, burns treatment, oral/maxillofacial surgery, breast reconstruction, and cosmetic procedures. Financially robust with FY2024 revenue of RMB768.9 million. No clinical trial results reported as it does not develop drugs.